Ironwood Pharmaceuticals, Inc. (FRA:I76)
2.840
-0.360 (-11.25%)
Last updated: Dec 1, 2025, 8:56 AM CET
Ironwood Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 338.99 | 351.41 | 442.74 | 410.6 | 413.75 | 389.52 | Upgrade | |
Revenue Growth (YoY) | -10.42% | -20.63% | 7.83% | -0.76% | 6.22% | -9.08% | Upgrade |
Cost of Revenue | -5.21 | 7.55 | 6.15 | 4.94 | 70.41 | 91.2 | Upgrade |
Gross Profit | 344.19 | 343.86 | 436.59 | 405.66 | 343.35 | 298.33 | Upgrade |
Selling, General & Admin | 96.55 | 144.27 | 142.11 | 115.99 | 111.13 | 140 | Upgrade |
Research & Development | 103.87 | 103.87 | 98.64 | 39.33 | - | - | Upgrade |
Operating Expenses | 200.42 | 248.14 | 240.75 | 155.32 | 111.13 | 140 | Upgrade |
Operating Income | 143.77 | 95.72 | 195.84 | 250.34 | 232.22 | 158.32 | Upgrade |
Interest Expense | -33.78 | -33.29 | -21.38 | -7.6 | -31.15 | -29.48 | Upgrade |
Interest & Investment Income | 3.4 | 4.47 | 18.97 | 9.5 | 0.73 | 1.5 | Upgrade |
Other Non Operating Income (Expenses) | 0.76 | 0.89 | -0.23 | 0.18 | -1.18 | -6.11 | Upgrade |
EBT Excluding Unusual Items | 114.15 | 67.79 | 193.2 | 252.42 | 200.61 | 124.24 | Upgrade |
Merger & Restructuring Charges | -20.58 | -2.59 | -45.82 | - | 0.04 | -15.38 | Upgrade |
Pretax Income | 93.57 | 65.2 | -948.07 | 252.42 | 200.66 | 108.86 | Upgrade |
Income Tax Expense | 65.02 | 64.32 | 83.49 | 77.36 | -327.79 | 2.69 | Upgrade |
Earnings From Continuing Operations | 28.55 | 0.88 | -1,032 | 175.07 | 528.45 | 106.18 | Upgrade |
Net Income to Company | 28.55 | 0.88 | -1,032 | 175.07 | 528.45 | 106.18 | Upgrade |
Minority Interest in Earnings | - | - | 29.32 | - | - | - | Upgrade |
Net Income | 28.55 | 0.88 | -1,002 | 175.07 | 528.45 | 106.18 | Upgrade |
Net Income to Common | 28.55 | 0.88 | -1,002 | 175.07 | 528.45 | 106.18 | Upgrade |
Net Income Growth | - | - | - | -66.87% | 397.71% | 393.73% | Upgrade |
Shares Outstanding (Basic) | 161 | 159 | 155 | 154 | 162 | 159 | Upgrade |
Shares Outstanding (Diluted) | 174 | 160 | 155 | 186 | 164 | 161 | Upgrade |
Shares Change (YoY) | 9.90% | 2.99% | -16.57% | 13.32% | 2.34% | 2.97% | Upgrade |
EPS (Basic) | 0.18 | 0.01 | -6.45 | 1.13 | 3.26 | 0.67 | Upgrade |
EPS (Diluted) | 0.18 | 0.01 | -6.45 | 0.96 | 3.21 | 0.66 | Upgrade |
EPS Growth | - | - | - | -69.98% | 386.36% | 378.84% | Upgrade |
Free Cash Flow | 67.65 | 103.41 | 183.15 | 273.63 | 261.63 | 166.99 | Upgrade |
Free Cash Flow Per Share | 0.39 | 0.65 | 1.18 | 1.47 | 1.59 | 1.04 | Upgrade |
Gross Margin | 101.53% | 97.85% | 98.61% | 98.80% | 82.98% | 76.59% | Upgrade |
Operating Margin | 42.41% | 27.24% | 44.23% | 60.97% | 56.12% | 40.64% | Upgrade |
Profit Margin | 8.42% | 0.25% | -226.37% | 42.64% | 127.72% | 27.26% | Upgrade |
Free Cash Flow Margin | 19.96% | 29.43% | 41.37% | 66.64% | 63.23% | 42.87% | Upgrade |
EBITDA | 145.68 | 97.73 | 197.41 | 251.76 | 233.74 | 160.69 | Upgrade |
EBITDA Margin | 42.97% | 27.81% | 44.59% | 61.31% | 56.49% | 41.25% | Upgrade |
D&A For EBITDA | 1.91 | 2.01 | 1.58 | 1.42 | 1.52 | 2.36 | Upgrade |
EBIT | 143.77 | 95.72 | 195.84 | 250.34 | 232.22 | 158.32 | Upgrade |
EBIT Margin | 42.41% | 27.24% | 44.23% | 60.97% | 56.12% | 40.64% | Upgrade |
Effective Tax Rate | 69.49% | 98.65% | - | 30.65% | - | 2.47% | Upgrade |
Revenue as Reported | 338.99 | 351.41 | 442.74 | 410.6 | 413.75 | 389.52 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.